Skip to main content

Table 1 Patient demographics and baseline characteristics (mITT population)

From: Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study

Parameter

Zishen Pingchan (n = 89)

Placebo (n = 87)

p-value

Male gender; n (%)

42 (47.7%)

45 (51.1%)

0.651b

Age; years mean ± SD

68.1 ± 8.0

66.4 ± 9.8

0.203a

Duration of PD; months mean ± SD

92.4 ± 48.1

80.8 ± 46.9

0.196a

MMSE score; median (IQR)

29 (27, 30)

29 (27, 30)

0.765c

UPDRS-III; mean ± SD

23.98 ± 11.86

23.93 ± 11.14

0.979a

LED; mean ± SD

246.38 ± 123.90

234.40 ± 141.63

0.224a

Hoehn-Yahr stage; n (%)

  

0.949b

Stage 1

Stage 1.5

Stage 2

Stage 2.5

Stage 3

Stage 4

11 (12.4%)

5 (5.6%)

43 (48.3%)

9 (10.1%)

20 (22.5%)

1 (1.1%)

8 (9.2%)

7 (8.0%)

42 (48.3%)

9 (10.3%)

19 (21.8%)

2 (2.3%)

 
  1. Parametric variables are presented as mean ± SD, non-parametric variables are presented as median (interquartile range) and categorical variables are presented as n (%)
  2. PD, Parkinson’s disease; UPDRS, Unified Parkinson Disease Rating Scale; MMSE, Mini-mental State Examination; SD, standard deviation; IQR, interquartile range; LED: Levodopa equivalent dose
  3. aTwo-sample t-test
  4. bChi-squared test
  5. cMann-Whitney U test